UK markets open in 43 minutes
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     
  • HANG SENG

    23,327.58
    -524.66 (-2.20%)
     
  • CRUDE OIL

    68.48
    -1.47 (-2.10%)
     
  • GOLD FUTURES

    1,794.00
    +8.80 (+0.49%)
     
  • DOW

    35,135.94
    +236.60 (+0.68%)
     
  • BTC-GBP

    42,511.74
    -947.07 (-2.18%)
     
  • CMC Crypto 200

    1,430.40
    +1.47 (+0.10%)
     
  • ^IXIC

    15,782.83
    +291.18 (+1.88%)
     
  • ^FTAS

    4,057.63
    +37.25 (+0.93%)
     

Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

CONTACT: Investor and Media Inquiries: Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting